

PRESSMEDDELANDE IDOGEN AB



Org nr. 556756-8521
Date: 23th of March, 2017

European patent granted for Idogen's vaccine technology

Idogen AB ("Idogen") announces that the European Patent Office ("EPO") will formally grant a patent application, covering the company's tolerogenic vaccine technology. The EPO approval strengthens the company's patent portfolio for the vaccine technology. A patent in the same patent family has already been granted in Japan and a Notice of Allowance has been received from the USA.

The European Patent Office issued in January 2017 a "Notice of intention to grant" and will now formally grant Idogen's Patent Application relating to induction of IDO for treatment of autoimmune diseases and rejection of transplanted organs. The patent, with patent No. EP2654758, belongs to Idogen's second patent family and covers Idogen's technology until 2031 in Europe. The granted patent will be validated in a number of strategically interesting countries in Europe. Idogen already has an issued patent in this patent family for Japan and has received a "Notice of Allowance" in the USA. A related patent application is pending in Canada.

Idogen's first patent family covers additional aspects of using zebularine for the treatment of autoimmune diseases and rejection of transplanted organs, which together with the second patent family creates broader protection for the company's product to potential competitors. The first patent family is previously granted in Europe and is pending in the USA.

CEO Lars Hedbys commented that "The granted patent in Europe is a significant endorsement. Idogen develops tolerogenic vaccines with high medical and commercial potential, and we have now secured patent protection for these methodologies in two major markets – Europe and Japan. We also have a Notice of Allowance issued in the USA".

For additional information about Idogen, please contact:

Lars Hedbys, CEO
Tel: +46 (0)46-275 63 30
E-mail: lars.hedbys@idogen.com

This is an English version of an original Swedish press release communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This constitutes information that Idogen AB is required to publish under the EU's Market Abuse Regulation. The information was submitted for publication through the above contact person on the 23th of March 2017.

Idogen develops tolerogenic vaccines which re-program the immune system. The term "tolerogenic" refers to that the immune system will tolerate the selected molecule after treatment. It represents a new treatment method for autoimmune diseases, organ rejection after transplantation and patients without treatment after developing antibodies against standard treatment. The first indication for the therapy will be patients with the bleeding disorder hemophilia A who have developed an immunological reaction against their necessary factor VIII replacement. The treatment method comprises cells from the patient's blood being reprogrammed to dendritic cells with the capacity to specifically counteract the adverse immune reaction. The company's technology platform has the potential to develop long-acting treatment of anti-drug antibodies as well as autoimmune diseases that currently cannot be cured. In addition, Idogen has the potential to change the transplantation market by reducing the need for immunosuppressive therapy after transplantation. Idogen was founded in 2008 based on a fundamental immunological discovery at Lund University. For more information, visit www.idogen.com